In a groundbreaking theory, scientists at Arizona State University's Biodesign Institute propose a unifying explanation for the molecular chaos driving Alzheimer's disease.

SAN ANTONIO – A new study from UT Health San Antonio has provided new insights into Alzheimer’s disease. Researchers have uncovered a genetic factor that may contribute to the risk of late onset of ...

Annovis Bio has commenced the treatment of first two subjects in a randomised Phase III clinical trial to assess the efficacy and safety of buntanetap in treating early Alzheimer's disease (AD). The ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

In a novel theory, scientists at Arizona State University's Biodesign Institute propose a unifying explanation for the ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

A new study found that older adults with fluctuating cholesterol levels—regardless of how high—could be 60% more likely to ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the two key pathological hallmarks of Alzheimer's—tau protein and beta-amyloid ...

A blood-based biomarker test may be a reliable method for predicting or ruling out Alzheimer’s disease-related pathology and ...

Readers worry that fraud may tarnish the field and slow the race for a cure. Also: Charles Blow’s farewell; treatment for ...